Kohl's Corporation vs Novartis AG — how do they compare? Kohl's Corporation trades at $18.83 (market cap $2.19B), while Novartis AG trades at $152.71 (market cap $291.04B). The key difference: Novartis AG is far larger — about 132.9× Kohl's Corporation's market cap, and Novartis AG pays the higher dividend (3.11%). Which is the better fit depends on your goals.
| KSS | NVS | |
|---|---|---|
Market Cap | $2.19B | $291.04B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $168.62 |
52-Week Low | $11.72 | $121.20 |
Enterprise Value | $8.29B | $332.36B |
Dividend Yield | 2.59% | 3.11% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Trailing returns across standard periods
Latest headlines on both assets
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →